Celaid Therapeutics Inc. is pleased to announce that its President and CEO, Nobuyuki Arakawa, will deliver a special lecture at Regenerative Medicine Expo Tokyo 2026 on Wednesday, May 20, 2026, from 10:00 to 11:00.
Regenerative Medicine Expo is one of the largest exhibitions in Japan dedicated to regenerative medicine, bringing together companies and technologies from across the field. In this lecture, we will present next-generation cell therapies leveraging our proprietary ex vivo expansion technology for human hematopoietic stem cells (HSCs).
<Regenerative Medicine Expo Tokyo 2026>
Dates: May 20 (Wed) – May 22 (Fri), 2026
Venue: Makuhari Messe
<Special Lecture (1) – Free Admission>
Click here for registration details
Date & Time : May 20 (Wed), 2026, 10:00–11:00
Title : Advancing Next-Generation Cell Therapy Through Hematopoietic Stem Cell Expansion Technology
Speaker:
Nobuyuki Arakawa
President & CEO, Celaid Therapeutics Inc.
[Lecture Overview]
This lecture will outline the development status of next-generation cell transplantation products for refractory hematologic diseases using ex vivo expansion technology for human hematopoietic stem cells (HSCs). It will also cover cutting-edge applications of this technology, including the generation of novel blood and immune cell modalities through iPSC-derived HSCs, as well as its expansion into ex vivo HSC gene therapy. The session will provide a comprehensive overview of the forefront of next-generation cell therapies enabled by this platform.
[Speaker Profile]
Nobuyuki Arakawa graduated from the Faculty of Science and Technology, Keio University in 2004, and received his Master’s degree in Engineering from Keio University in 2006. After working at Accenture, he was engaged in new business development and project management across regenerative medicine, AI/IoT, and healthcare sectors. In 2020, he co-founded Celaid Therapeutics with the aim of commercializing innovative cell therapy products based on human hematopoietic stem cell expansion technology. He currently serves as President and CEO.